Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: Results from a phase II prospective trial

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 8-14

  Kies, Merrill S ^a   Holsinger, Floyd Christopher ^a   Lee, J Jack ^a   William Jr , William N ^a   Glisson, Bonnie S ^a   Lin, Heather Y ^a   Lewin, Jan S ^a   Ginsberg, Lawrence E ^a   Gillaspy, Katharine A ^a   Massarelli, Erminia ^a   Byers, Lauren ^a   Lippman, Scott M ^a   Hong, Waun K ^a   El Naggar, Adel K ^a   Garden, Adam S ^a   Papadimitrakopoulou, Vassiliki ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; PACLITAXEL; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; ALLERGIC REACTION; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DEHYDRATION; DESQUAMATION; DIARRHEA; DRUG DOSE REDUCTION; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLICULITIS; FOLLOW UP; HEAD AND NECK CARCINOMA; HEMATOLOGIC DISEASE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SENSORY NEUROPATHY; SQUAMOUS CELL CARCINOMA; TASTE DISORDER; THROMBOCYTOPENIA; TINNITUS; TREATMENT RESPONSE; VOMITING; XEROSTOMIA; AGED; HEAD AND NECK TUMOR; ISOLATION AND PURIFICATION; MIDDLE AGED; MORTALITY; PAPILLOMA VIRUS; PROSPECTIVE STUDY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; PAPILLOMAVIRIDAE; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 73949102962     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.0425     Document Type: Article

References (31)

1. Adelstein DJ, Leblanc M: Does induction chemotherapy have a role in the management of locoregionally advanced squamous cell head and neck cancer? J Clin Oncol 24:2624-2628, 2006
2. Brockstein B, Haraf DJ, Rademaker AW, et al: Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol 15:1179-1186, 2004
3. Garden AS: Where are the at-risk cervical nodes? Int J Radiat Oncol Biol Phys 58:1-2, 2004
4. Garden AS, Asper JA, Morrison WH, et al: Is concurrent chemoradiation the treatment of choice for all patients with Stage III or IV head and neck carcinoma? Cancer 100:1171-1178, 2004
5. Pignon JP, Bourhis J, Domenge C, et al: Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data - Meta-Analysis of Chemotherapy on Head and Neck Cancer Collaborative Group. Lancet 355:949-955, 2000
6. Monnerat C, Faivre S, Temam S, et al: End points for new agents in induction chemotherapy for locally advanced head and neck cancers. Ann Oncol 13:995-1006, 2002
7. Hitt R, Lopez-Pousa A, Martinez-Trufero J, et al: Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 23:8636-8645, 2005
8. Vermorken JB, Remenar E, van Herpen C, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695-1704, 2007
9. Posner MR, Hershock DM, Blajman CR, et al: Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 357:1705-1715, 2007
10. Cohen EE, Lingen MW, Vokes EE: The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22:1743-1752, 2004
11. Vokes EE, Stenson K, Rosen FR, et al: Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: Curative and organ-preserving therapy for advanced head and neck cancer. J Clin Oncol 21:320-326, 2003
12. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
13. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
14. Ang KK, Garden AS: Radiotherapy for Head and Neck Cancers Indications and Techniques (ed 3). Philadelphia, PA, Lippincott Williams & Wilkins, 2006
15. Ang KK, Peters LJ, Weber RS, et al: Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx. Int J Radiat Oncol Biol Phys 19:1339-1345, 1990
16. Logemann J: Evaluation and Treatment of Swallowing Disorders (ed 2). Austin, TX, Pro-Ed, 1998, pp 168-180
17. Rosenbek JC, Robbins JA, Roecker EB, et al: A penetration-aspiration scale. Dysphagia 11:93-98, 1996
18. List MA, Ritter-Sterr C, Lansky SB: A performance status scale for head and neck cancer patients. Cancer 66:564-569, 1990
19. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
20. Haddad RI, Shin DM: Recent advances in head and neck cancer. N Engl J Med 359:1143-1154, 2008
21. Wanebo HJ, Ghebremichael M, Burtness B, et al: Phase II evaluation of cetuximab (C225) combined with induction paclitaxel and carboplatin followed by C225, paclitaxel, carboplatin, and radiation for stage III/IV operable squamous cancer of the head and neck (ECOG, E2303). J Clin Oncol 25: 302s, 2007 (suppl; abstr 6015)
22. Ackerstaff AH, Balm AJ, Rasch CR, et al: First-year quality of life assessment of an intra-arterial (RADPLAT) versus intravenous chemoradiation phase III trial. Head Neck 31:77-84, 2009
23. Machtay M, Moughan J, Trotti A, et al: Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 26:3582-3589, 2008
24. Shiley SG, Hargunani CA, Skoner JM, et al: Swallowing function after chemoradiation for advanced stage oropharyngeal cancer. Otolaryngol Head Neck Surg 134:455-459, 2006
25. Eisbruch A, Lyden T, Bradford CR, et al: Objective assessment of swallowing dysfunction and aspiration after radiation concurrent with chemotherapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 53:23-28, 2002
26. Langerman A, Maccracken E, Kasza K, et al: Aspiration in chemoradiated patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 133:1289-1295, 2007
27. Gillison ML, D'Souza G, Westra W, et al: Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100:407-420, 2008
28. Gillison ML, Harris J, Westra W, et al: Survival outcomes by tumor human papillomavirus (HPV) status in stage III-IV oropharyngeal cancer (OPC) in RTOG 0129. J Clin Oncol 27:301s, 2009 (suppl; abstr 6003)
29. Kumar B, Cordell KG, Lee JS, et al: Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys 69:S109-S111, 2007 (suppl)
30. Fakhry C, Westra WH, Li S, et al: Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100: 261-269, 2008
31. Kumar B, Cordell KG, Lee JS, et al: EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol 26:3128-3137, 2008